Skip to main content
OpenTrials
Completed

NCT Number: NCT06457152

Multi-Center Project: Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure

This study will test an automated, electronic health record (EHR-)embedded alert to improve prescribing of guideline-directed medical therapy for patients with heart failure and reduced ejection fraction (HFrEF). The investigators have previously tested and implemented this alert at NYU Langone Health (NYULH), and will now test and implement this alert across three other health systems.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heart Failure Cardiovascular Diseases Heart Diseases

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Massachusetts, Boston, Massachusetts, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with an encounter visit at participating cardiology practice during the study period
  • Patient with EF of less than or equal to 40% on most recent echocardiogram at the time of visit
  • Patient ages 18-90

Exclusion criteria

  • Pregnancy
  • Ventricular assist device
  • Hospice
  • Cardiac amyloid
  • Medication-specific exclusion for MRA: most recent systolic blood pressure less than 105 mm Hg, most recent potassium < 5.1, any potassium > 5.5, most recent glomerular filtration rate < 30 (using MDRD equation), or a documented MRA allergy.

Treatment and study plan

EHR-Emedded Alert

Other

For patients randomized to the intervention group, an automated, EHR-embedded alert will be visible in the patient's chart that promotes appropriate medical therapy for patients with HFrEF.

Primary outcomes

  1. Number of Patients with a Prescription for Mineralocorticoid Antagonists (MRA)

    Time frame: Up to Day 30

    Measured at the prescription encounter level using patient EHR data.

Secondary outcomes

  1. Number of Patients with a Prescription for Beta-Blocker (BB)

    Time frame: Up to Day 30

    Measured at the prescription encounter level using patient EHR data.

  2. Number of Patients with a Prescription for ACE-I/ARB/ARNI

    Time frame: Up to Month 36

    Prescription for angiotensin converting enzyme-inhibitors/angiotensin receptor blockers/angiotensin receptor neprilysin inhibitors (ACE-I/ARB/ARNI) measured at the prescription encounter level using patient EHR data.

  3. Number of Patients with a Prescription for Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i)

    Time frame: Up to Month 36

    Measured at the prescription encounter level using patient EHR data.

  4. Number of Patients with Hyperkalemia

    Time frame: Up to Month 36

    Measured using patient EHR data.

  5. Number of Patients who are Hospitalized

    Time frame: Up to Month 36

    Measured using patient EHR data.

  6. Number of Patients who are Hospitalized for Heart Failure (HF)

    Time frame: Up to Month 36

    Measured using patient EHR data.

Sponsors and collaborators

Lead sponsor

NYU Langone Health

Other

Collaborators

  • Massachusetts General Hospital
  • OhioHealth
  • University of Pennsylvania

Registry information

Official study title

Multi-Center Project: BETTER CARE - HF (Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure)

Acronym: BETTER CARE-HF

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Jun 13, 2024
Registry last updated
May 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.